Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
HER2-low and HER2-ultra-low salivary gland carcinomas: an exploratory study | Synapse
March 3, 2026
HER2-low and HER2-ultra-low salivary gland carcinomas: an exploratory study
BX
Bin Xu
AL
Ahmed Lazim
Memorial Sloan Kettering Cancer Center
DR
Dibisha Roy
See all
Key Points
Salivary gland carcinomas exhibit varying HER2 expression levels, influencing classification.
Specifically, both HER2-low and HER2-ultra-low cases present unique characteristics essential for treatment strategies.
Observational analysis focused on biomarkers related to HER2 expression in diverse carcinoma subtypes.
Highlights the need for further investigation into HER2-targeted therapies in these rare cancers.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Xu et al. (Thu,) studied this question.
synapsesocial.com/papers/69a75e5ac6e9836116a28d59
https://doi.org/https://doi.org/10.1007/s00428-026-04421-5